Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]Zr-DFO-AMI: sourced facts only. name: "[89Zr]Zr-DFO-AMI specifically binds EGFR and c-MET." [DOI:10.1158/1538-7445.am2026-lb491]; target: "[89Zr]Zr-DFO-AMI specifically binds EGFR and c-MET." [DOI:10.1158/1538-7445.am2026-lb491]; target: "[89Zr]Zr-DFO-AMI specifically binds EGFR and c-MET." [DOI:10.1158/1538-7445.am2026-lb491]; developer: "University of Alabama at Birmingham, Birmingham, AL." [DOI:10.1158/1538-7445.am2026-lb491]; modality: "AMI was conjugated to p-SCN-Bn-deferoxamine (DFO) and radiolabeled with Zirconium-89 to generate [89Zr]Zr-DFO-AMI." [DOI:10.1158/1538-7445.am2026-lb491]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [89Zr]Zr-DFO-AMI.